Elevated S6K1 have been reported in 9%–14% of breast cancer patients and studies have demonstrated that elevated S6K1 drives palbociclib resistance via activation of c-Myc signaling pathways in preclinical models and clinical breast cancer samples (Mo et al., 2022). Here, MYC is linked to breast cancer.